Richard Nolan Townsend, serving as the Chief Executive Officer of Lexeo Therapeutics, Inc. (NASDAQ:LXEO), has executed a transaction involving the sale of 25,947 shares of the company's common stock. This activity occurred on July 1, 2026, resulting in a total realized value of $116,242. The shares were disposed of at varying prices within a range of $4.3402 to $4.7507, establishing a weighted average sale price of $4.48 per share. The primary driver for this divestment was the necessity to cover tax obligations associated with the release of performance Restricted Stock Units.
This recent sale takes place within a context of significant price depreciation for the stock, which has fallen by 55% over the past six months. Despite this downward trajectory, data sourced from InvestingPro suggests that the company may currently be trading below its intrinsic value, supported by a market capitalization of $366 million. The transaction follows an acquisition made by Mr. Townsend on June 29, 2026, where he obtained 67,000 shares of common stock at a price of $0 per share. Following these combined activities, Mr. Townsend's direct ownership in Lexeo Therapeutics common stock totals 377,817 shares. This figure includes 252,130 Restricted Stock Units, which each confer a contingent right to receive one share of the company's common stock.
Key Points:
- CEO Richard Townsend sold 25,947 shares for $116,242 to cover tax obligations from vesting RSUs.
- Lexeo Therapeutics has published Phase I/II study results for gene therapy LX2006 in JAMA Cardiology, involving 17 participants evaluated over 6 to 36 months.
- Raymond James has reiterated a Strong Buy rating with a $25 price target, noting the company is awaiting final FDA feedback on the SUNRISE-FA 2 trial protocol.
Risks and Uncertainties:
- The stock has experienced a 55% decline over the past six months, indicating market volatility and potential investor caution.
- The company remains dependent on regulatory outcomes, specifically awaiting final FDA feedback on the pivotal SUNRISE-FA 2 trial protocol.
- The pivotal SUNRISE-FA 2 trial will involve a small cohort of 13 participants receiving LX2006 and 13 untreated control participants, without a placebo or sham procedure, which may limit comparative data scope.
In related developments, Lexeo Therapeutics has released findings from Phase I/II studies concerning its gene therapy LX2006, aimed at treating Friedreich ataxia. These results were published in JAMA Cardiology and encompassed 17 participants who underwent an intravenous infusion of LX2006. The evaluation period for these participants ranged from 6 to 36 months. Furthermore, the company has finalized the protocol and statistical analysis plan for its pivotal SUNRISE-FA 2 trial. This study will include 13 participants receiving LX2006 and 13 untreated control participants. Notably, this trial design will not incorporate a placebo or sham procedure for the control group. Market sentiment remains supported by Raymond James, which has maintained a Strong Buy rating on the stock with a price target of $25. The firm highlighted that Lexeo is currently awaiting final FDA feedback regarding the pivotal trial protocol for SUNRISE-FA 2. These activities underscore the company's ongoing efforts to advance its gene therapy portfolio.
Lexeo Therapeutics
Follow
Analyze LXEO
Included in our AI-picked strategies
Review strategies
4.45
-0.21
(-4.40%)
Closed
15:59:59
USD
4.45
0.00
(0.00%)
After Hours
16:10:04
1D
1W
6M
1Y
5Y
Max
Created with Highcharts 11.4.8
14:00
15:00
16:00
17:00
18:00
19:00
4.2
4.4
4.6
Analyze LXEO
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
See the trade on LXEO, but can't pull the trigger?
Most traders can read a chart. The hard part is the moment: entry window open, pattern forming, and you're still waiting for more confirmation. That's the conviction gap — and our chart analysis closes it. Unlike other AIs that just read data, our Vision AI literally "sees" your charts and hands you a complete trading plan: entry, stop-loss, and profit target in under 60 seconds. Know exactly what to do next, every time.
Try Chart Analysis for LXEO